Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Agios today announced financial results and updates for the third quarter ended September 30, 2025.
August 14, 2025 08:30 ET | Source: Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study, Unlocking Pathways for Gene-Based and Repurposed Therapies

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, Inc. (OTC: FITY), a leader in AI-powered drug repurposing and precision medicine, today announced the...
August 06, 2025 10:16 ET | Source: Spherix Global Insights

Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is...
July 31, 2025 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.
May 01, 2025 11:42 ET | Source: Spherix Global Insights

Gene Therapy Momentum Builds Among Hematologists in Sickle Cell Disease Management Despite Ongoing Access Barriers, According to Spherix Global Insights

EXTON, PA, May 01, 2025 (GLOBE NEWSWIRE) -- Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks....
May 01, 2025 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Agios Pharmaceuticals, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2025.
April 14, 2025 12:02 ET | Source: AB Science

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET AMERICAIN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE Paris, 14 avril 2025, 18h ...
April 14, 2025 12:02 ET | Source: AB Science

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CET AB Science SA...
January 22, 2025 08:00 ET | Source: IMMvention Therapeutix, Inc.

IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a...
January 13, 2025 05:39 ET | Source: Research and Markets

Rising Incidence and Newborn Screening Programs Spur Rapid Growth in Sickle Cell Anemia Diagnostics

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Sickle Cell Anemia Testing and Screening Market by Technology, by Age Group, End-User, and By Region" report has been added to ...